Clinical trial NCT00780039: A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
Official title: Phase II, Open-Label, Study of CAELYX and Carboplatin Intermediate Platinum-Sensitive (6-12 Months Treatment-free Interval) Relapsed Epithelial Ovarian Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ovarian Neoplasms
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: Princess Margaret Hospital, Canada
First posted: 2008-10-24
Enrollment: 58
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Doxorubicin has been used to treat ovarian cancer as part of different combination therapies, but high cumulative doses should be avoided because of the risk of cardiotoxicity. Pegylated Liposomal Doxorubicin (Caelyx) has been developed to reduce the risk of cardiotoxicity. The purpose of this study is to evaluate the safety and efficacy of Caelyx in combination with carboplatin in women with recurrent ovarian cancer.


Eligibility criteria: Inclusion Criteria:

* Age \>=18 years old
* Subject must have histological diagnosis of epithelial ovarian cancer
* Subject must have received a taxane and platinum regimen and have maintained a treatment-free status for at least six months and not more than twelve months following completion of first line therapy.
* Subject must have measurable ovarian cancer by appropriate radiological imaging.
* ECOG performance Score of 0 or 1.
* Subject's life expectancy must be \> 6 months.
* Subject must have normal organ function, except if abnormal due to tumor involvement:

  * Adequate bone marrow function (platelets \>=100 X 10\^9/L, hemoglobin \>=100 g/L, neutrophils \>=1.5 X 10\^9/L)
  * Adequate renal function (serum creatinine\<=1.5 X the upper limit of normal (ULN)
  * Adequate liver function (bilirubin and AST or ALT\<=2 times ULN, unless related to primary disease.
* MUGA scan must indicate left ventricular ejection fraction above 90%.
* Women of childbearing potential must be using adequate contraception (prescribed under medical supervision) and have a negative pregnancy test at the time of enrollment.
* Subject must be able to sign written informed consent.

Exclusion Criteria:

* Subject who is pregnant or is breast feeding.
* Subject who has history of cardiac disease, with New York Heart Association Class II or greater.
* Subject with a history of severe hypersensitivity reactions to products containing Cremophor® EL.
* Subject with clinically significant hepatic disease.
* Subject who has uncontrolled bacterial, viral, or fungal infection.
* Subject who exhibits confusion or disorientation.
* Subject with any condition that would prevent adequate follow-up.
* Subject with a history of prior malignancy treated with systemic chemotherapy or radiotherapy.
* Subject who has received two or more prior chemotherapy regimens for ovarian cancer.

Primary outcomes:
measure: Complete response rate, according to RECIST criteria; Partial response rate, according to RECIST criteria
timeFrame: Complete or partial response: re-evaluation 4 weeks later to confirm response; Upon completion of chemotherapy: follow-up every 2 months until documentation of progressive disease; All patients will be followed for a minimum of one year for survival
Secondary outcomes:
measure: Safety and tolerability; Duration of response; CA-125 response; Time to progression; Overall survival
timeFrame: All patients will be followed for a minimum of one year for survival
Other outcomes:
Locations:
Study officials:
References:
citation: Li KJ, Garoff H. Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3650-4. doi: 10.1073/pnas.95.7.3650.
citation: Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller WH Jr, Pouliot JF. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol. 2009 Sep;114(3):410-4. doi: 10.1016/j.ygyno.2009.04.037. Epub 2009 Jun 10.